Izak Herschitz, MD
Ophthalmology · Brooklyn, NYNPI 1700969763
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Alcon at 27.7% of the total. 2025 is the largest year on record at $143, 5.4 times the $26 reported in 2021. That places this record below the midpoint for ophthalmology clinicians in NY, where the typical reported total is $1,047.
Across 14 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$96
- Tarsus Pharmaceuticals, Inc.$95
- Mallinckrodt Hospital Products Inc.$90
- Incyte Corporation$23
- Oyster Point Pharma, Inc.$22
- Amgen$22
What the payments were for
- Food & beverage$349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 4 | $96 |
| Tarsus Pharmaceuticals, Inc. | 3 | $95 |
| Mallinckrodt Hospital Products Inc. | 4 | $90 |
| Incyte Corporation | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $22 |
| Amgen | 1 | $22 |
How this compares
$349 in reported general payments places this provider in the 30th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 495 | $340,009 |
| XiidraLifitegrast | 183 | $124,080 |
| Alphagan PBrimonidine Tartrate | 170 | $52,020 |
| LotemaxLoteprednol Etabonate | 87 | $33,873 |
| Cyclosporine | 101 | $31,936 |
| CombiganBrimonidine Tartrate/Timolol | 95 | $24,130 |
| Brimonidine Tartrate | 251 | $21,062 |
| Loteprednol Etabonate | 105 | $19,311 |
| ProlensaBromfenac Sodium | 56 | $18,987 |
| LumiganBimatoprost | 44 | $16,345 |
| TobradexTobramycin/Dexamethasone | 44 | $11,402 |
| AlrexLoteprednol Etabonate | 18 | $7,566 |
| ZerviateCetirizine Hcl | 28 | $6,157 |
| Bromfenac Sodium | 22 | $5,545 |
| Latanoprost | 679 | $5,101 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Brooklyn
- David RubaltelliBrooklyn$8.9M
- Irene GladsteinBrooklyn$94K
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.